Caribou Biosciences, Inc.

CRBU Healthcare Biotechnology

Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.

0.47 0.00 0.00%
Market cap
$49.8M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
—
F-score
3/9
Altman Z
−5.00
Beneish M
−3.93
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
23.39 13.31 16.26 17.71
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(8.63) (7.13) (6.75) (7.80)
P/B ratio
1.53 1.22 1.79 1.81
EV/Sales
7.54 0.82 5.76 6.52
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(0.55) (0.08) (0.63) (0.49)
Current Ratio
5.54 5.71 6.22 6.49
Net Debt/EBITDA
5.08 4.99 4.54 4.54
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(72.96%) (100.00%) (74.74%) (61.36%)
Free Cash Flow Yield
(58.76%) (75.66%) (55.80%) (74.71%)
Free Cash Flow per Share
(1.59) (0.22) (0.28) 0.62
Book value per Share
1.52 1.31 1.06 0.97
Free Cash Flow
(147.93) (20.61) (27.06) 62.80
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates